FDA Grants EUA for Convalescent Plasma in Hospitalized COVID-19 Patients

Source: BioSpace

The FDA reversed itself Sunday following pressure from the White House and announced an Emergency Use Authorization for convalescent plasma as a treatment for patients who have contracted COVID-19, according to a BioSpace report.

In its announcement, the FDA said it granted the EUA for convalescent plasma in hospitalized patients because it “may be effective in treating COVID-19 and that the known and potential benefits of the product outweigh the known and potential risks of the product.” The FDA said there is a reason to believe that the use of convalescent plasma may also be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitalized patients.

Read the full article.

Related Content